This document is scheduled to be published in the Federal Register on 2026-11-02 and available online at https://www.federalregister.gov/d/2026-22328, and on https://govinfo.gov

de 3110-01

OFFICE OF MANAGEMENT AND BUDGET

Request for Information; Reopening of Comment Period

AGENCY: Office of Management and Budget.

ACTION: Request for information; reopening of response period.

SUMMARY: The Office of Management and Budget (OMB) published in the Federal Register a request for information (RFI) regarding new and unused (idle) domestic, U.S.-based, and near shore production capabilities for Finished Dose Forms, Active Pharmaceutical Ingredients, and Key Starting Materials associated with the Administration for Strategic Preparedness and Response (ASPR) 86 List of essential medicines. The RFI provided for a 30-day response period which closed on October 26, 2026. OMB has determined that reopening the comment period until November 27, 2026, is appropriate. This action will allow interested parties additional time to prepare information and responses.

DATES: The response period for the notice published on September 25, 2026 (91 FR 60983), regarding the RFI on Domestic and Near Shore Manufacturing of Essential Medicines on the ASPR 86 List, is reopened. Responses must be received on or before November 27, 2026.

ADDRESSES: Responses must be submitted electronically through *regulations.gov.* Mailed paper submissions will not be accepted, and electronic submissions received after the deadline may not be considered.

Instructions: Federal eRulemaking Portal: Go to *www.regulations.gov* search "Domestic and Near Shore Manufacturing of Essential Medicines RFI" to submit your comments electronically. Information on how to use *Regulations.gov,* including instructions for accessing agency documents, submitting comments, and viewing the docket, is available on the site under "FAQ" (*https://www.regulations.gov/faq*). Should you choose to include proprietary information or confidential business information in your submission, please ensure you use appropriate markings and handling instructions to alert OMB as to the nature of information being submitted

and maintain proper handling. Your response will be shared with other Federal agencies and entities.

Privacy Act Statement: OMB is issuing this request for information (RFI) pursuant to its authorities under 31 U.S.C. 501 *et seq.* Comments and commenter information are maintained under the OMB Public Input System of Records, OMB/INPUT/01. The system of records notice accessible at 88 FR 20913 (*https://www.federalregister.gov/documents/2023/04/07/2023-07452/privacy-act-of-1974-system-of-records*) includes a list of routine uses associated with the collection of this information.

Disclaimer: Participation in this RFI is strictly voluntary. OMB will use your feedback to inform sound decision-making on topics related to this RFI regarding potential government-wide actions to revitalize the domestic manufacturing base, create new opportunities for U.S. firms and workers, and position U.S. businesses to compete and lead globally in strategic industries. This announcement should not be construed as a commitment of any kind by the U.S. Government. The U.S. Government is in no way liable to pay for or reimburse any companies or entities that respond to this announcement. Nothing in this announcement constitutes an obligation on the part of the U.S. Government. A response to this RFI will not be viewed as a binding commitment to develop or pursue the project or ideas discussed.

FOR FURTHER INFORMATION CONTACT: Please direct questions regarding this Notice to Robert Orr, Deputy to the Associate Director of Economic Policy, Office of Management and Budget, tel: 202-395-1390, or email the Made in America Office at *MadeInAmerica@omb.eop.gov* with "Domestic and Near Shore Manufacturing of Essential Medicines on the ASPR 86 List" in the subject line.

SUPPLEMENTARY INFORMATION: On September 25, 2026, OMB published in the Federal Register an RFI soliciting responses on new and unused (idle) domestic, U.S.-based, and near shore production capabilities for Finished Dose Forms, Active Pharmaceutical Ingredients, and Key Starting Materials associated with the ASPR 86 List of essential medicines. The RFI

stated that the response period would close on October 26, 2026. OMB has received requests to reopen the response period. Reopening the response period will allow interested parties additional time to prepare information and comments. Therefore, OMB is reopening the response period for the RFI until November 27, 2026.

Michael Stumo,

Director, Made in America Office.

[FR Doc. 2026-22328 Filed: 10/30/2026 8:45 am; Publication Date: 11/2/2026]